Seeking Alpha

jjjorgen

jjjorgen
Send Message
View as an RSS Feed
View jjjorgen's Comments BY TICKER:
Latest  |  Highest rated
  • Prognosticating 2014: Athersys Shares Will Continue To Climb [View article]
    Thanks for another great write-up U.S.B!! TooSmart, you prove yourself over and over for your dislike in Athersys. I think you need to spend your time in the ACTC, PSTI, and NWBO boards pumping them up. But of course, we all know you're shorting ATHX here. Good Luck with that!
    Jan 7, 2014. 04:16 PM | 7 Likes Like |Link to Comment
  • Aeterna Zentaris spikes as FDA accepts NDA for filing [View news story]
    Pathetic management in place for this company. Over a year late on this NDA. Drug may be worth $2 million a year in sales. Sell on the slight rise.
    Jan 6, 2014. 02:01 PM | 1 Like Like |Link to Comment
  • Athersys: Remarkable Treatment For Ischemic Stroke Feasibly On The Way [View article]
    WST~ Couldn't have said it better. I know those of us who have researched the heck out of this company get tired of defending it, but one day we'll be able to say, Told you so! I'm to the point of not saying anything, as 2014 will speak for itself. Glad you're on the right side of the argument!
    Jan 6, 2014. 09:51 AM | 1 Like Like |Link to Comment
  • Athersys: Remarkable Treatment For Ischemic Stroke Feasibly On The Way [View article]
    Very informative article for the uneducated in Athersys and MultiStem. My own research has resulted in this being the largest position in my portfolio. 2014 will be a defining year, and I feel $10/shr is well within range.
    Jan 5, 2014. 11:38 AM | 3 Likes Like |Link to Comment
  • Athersys, Inc.: '2014' [View article]
    WST~ Saw it, great article!! Thanks, looking forward to 2014!
    Nov 23, 2013. 01:07 PM | 1 Like Like |Link to Comment
  • Athersys, Inc.: '2014' [View article]
    I love this statement from Gil:
    Recently, we conducted a trial investigator meeting to review study progress in key aspects of the trial with the clinicians and study site coordinators. During the meeting, leading clinicians from a couple of the highest-enrolling sites shared their experience with the other study site investigators and site coordinators, and it's fair to say there was a lot of excitement at the meeting. Our enthusiasm for the study remains very high. We believe that this approach has tremendous potential and could represent a major advance in stroke clinical care.

    In the U.S., enrollment continues to ramp up as we build momentum, with enrollment rates improving with the addition of new sites and increased site activity levels and impact of recent minor protocol amendments.

    Momentum has also been building in Europe. In August, we received formal ethics approval to initiate the trial in the U.K. And since that time, we have conducted site training and have been completing certain logistical activities, such as finalizing site contracts. This process has taken a bit longer than we had hoped, but the initial U.K. sites are now in the process of launching. We expect 4 sites to be operational in the next few weeks, with 2 more added early next year.

    Given that these sites tend to see a larger number of stroke patients than many of the sites in the U.S., we anticipate that this will continue to drive momentum for the study. Our objective is the disclosure of the initial results from the study sometime next summer
    Nov 23, 2013. 10:38 AM | 1 Like Like |Link to Comment
  • Athersys, Inc.: '2014' [View article]
    May I be first to commend and congratulate you on a comprehensive analysis of Athersys, and their current state of being. I too listened to the conference call, and have researched the Athersys management team. I believe they hold they keys to success in propelling us forward, and I have complete faith in them. A short analysis article on Athersys management team one day would be nice to see. Kudos, and thanks again for the write up!
    Nov 18, 2013. 02:23 PM | 7 Likes Like |Link to Comment
  • Exciting Stem Cell Investment Candidates With Near-Term Catalysts [View article]
    Thanks CF!! Great article, as always! Huge fan and holder of Athersys! Will be an exciting 2014 for them. Expect another double by end of 2014. GLTA
    Nov 12, 2013. 04:32 PM | 3 Likes Like |Link to Comment
  • Investments In Targeting HER2 For The Treatment Of Cancer [View article]
    Well written, CF! With Dendreon putting itself up for sale, a BIO with deeper pockets could make better headway.
    Oct 28, 2013. 10:54 AM | Likes Like |Link to Comment
  • GTx: 4 Reasons Why This $1 Biotech Stock Could Be Poised For A Big Rebound [View article]
    Now in @ $1.75, see $2.25 in the near future!
    Oct 23, 2013. 03:57 PM | Likes Like |Link to Comment
  • Agenus: Some More Thoughts On The Potential For Prophage [View article]
    Mr. Smith, Adam F is ripping these results what is your opinion?? TIA.
    http://yhoo.it/15SniOn
    Oct 7, 2013. 09:59 PM | Likes Like |Link to Comment
  • Santarus: Recent Pullback Presents A Buying Opportunity [View article]
    Excellent synopsis, and I'm a strong believer in Navillier guidance also. I've been scouring the internet for Uceris usage feedback, and find a lot of strong believers in it's effectiveness. November shall show great earnings, and I expect a $30 pps by year-end. Thanks!!
    Oct 5, 2013. 11:37 AM | 1 Like Like |Link to Comment
  • Santarus' Impressive Margins, High ROIC, And Low Financial Risk Boost Upside Potential [View article]
    Way to capitulate, Derek!
    Oct 1, 2013. 05:56 PM | Likes Like |Link to Comment
  • Santarus' Impressive Margins, High ROIC, And Low Financial Risk Boost Upside Potential [View article]
    Santarus is a specialty biopharmaceutical company. Headquartered in San Diego,CA, the company will be added to the S&P SmallCap 600 GICS Pharmaceuticals Sub-Industry index.
    Sep 25, 2013. 05:49 PM | Likes Like |Link to Comment
  • Santarus' Impressive Margins, High ROIC, And Low Financial Risk Boost Upside Potential [View article]
    Technically, the stock is weak. But that is the glass is half empty synopsis. The fundamentals are great for Santarus, and I have personally been accumulating down here. I continue to research message boards and blogs from people using Uceris, and I'm greatly impressed. Do you do more than technical analysis? This will be more of a block buster than initially thought. Did you see the revenue guidance increase? I would not short here, at the worst, I'd hold. Don't let an insider sale sway you, he was up 100%, and maybe wanted to build a new home? Who knows! No matter what, I wait until seeing November 4 earnings before doing anything!
    Sep 23, 2013. 04:55 PM | 3 Likes Like |Link to Comment
COMMENTS STATS
323 Comments
235 Likes